These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1042 related articles for article (PubMed ID: 19695548)

  • 1. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trials.
    Waseda K; Hasegawa T; Ako J; Honda Y; Grube E; Whitbourn R; Ormiston J; O'Shaughnessy CD; Henry TD; Overlie P; Schwartz LB; Sudhir K; Chevalier B; Gray WA; Yeung AC; Fitzgerald PJ;
    Circ J; 2010 Nov; 74(11):2334-9. PubMed ID: 20890052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB
    JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial).
    Sakurai R; Hongo Y; Yamasaki M; Honda Y; Bonneau HN; Yock PG; Cutlip D; Popma JJ; Zimetbaum P; Fajadet J; Kuntz RE; Wijns W; Fitzgerald PJ;
    Am J Cardiol; 2007 Sep; 100(5):818-23. PubMed ID: 17719326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
    JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.
    Leon MB; Mauri L; Popma JJ; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; McLaurin BT; Solomon SL; Douglas JS; Ball MW; Caputo RP; Jain A; Tolleson TR; Reen BM; Kirtane AJ; Fitzgerald PJ; Thompson K; Kandzari DE;
    J Am Coll Cardiol; 2010 Feb; 55(6):543-54. PubMed ID: 20152559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III.
    Miyazawa A; Ako J; Hongo Y; Hur SH; Tsujino I; Courtney BK; Hassan AH; Kandzari DE; Honda Y; Fitzgerald PJ;
    Am Heart J; 2008 Jan; 155(1):108-13. PubMed ID: 18082499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of zotarolimus-eluting stents with sirolimus-eluting and paclitaxel-eluting stents: intimal hyperplasia and vascular changes assessed by volumetric intravascular ultrasound analysis.
    Kang SJ; Mintz GS; Park DW; Lee SW; Kim YH; Lee CW; Han KH; Kim JJ; Park SW; Park SJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):139-45. PubMed ID: 21364151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of diabetes mellitus on vessel response in the drug-eluting stent era: pooled volumetric intravascular ultrasound analyses.
    Sakata K; Waseda K; Kume T; Otake H; Nakatani D; Yock PG; Fitzgerald PJ; Honda Y
    Circ Cardiovasc Interv; 2012 Dec; 5(6):763-71. PubMed ID: 23149332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of polymer formulations on neointimal proliferation after zotarolimus-eluting stent with different polymers: insights from the RESOLUTE trial.
    Waseda K; Ako J; Yamasaki M; Koizumi T; Sakurai R; Hongo Y; Koo BK; Ormiston J; Worthley SG; Whitbourn RJ; Walters DL; Meredith IT; Fitzgerald PJ; Honda Y
    Circ Cardiovasc Interv; 2011 Jun; 4(3):248-55. PubMed ID: 21586691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of vascular response to the everolimus-eluting stent versus the paclitaxel-eluting stent: intravascular ultrasound results from the SPIRIT III trial.
    Yamasaki M; Tsujino I; Lima-Filho MO; Ako J; Shimohama T; Hasegawa T; Sakurai R; Sudhir K; Stone GW; Waseda K; Honda Y; Fitzgerald PJ
    EuroIntervention; 2012 Oct; 8(6):724-31. PubMed ID: 23086791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial.
    Kim JS; Jang IK; Fan C; Kim TH; Kim JS; Park SM; Choi EY; Lee SH; Ko YG; Choi D; Hong MK; Jang Y
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1240-7. PubMed ID: 20129551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Liberté stents in de novo native coronary artery lesions.
    Otake H; Honda Y; Courtney BK; Shimohama T; Ako J; Waseda K; Macours N; Rogers C; Popma JJ; Abizaid A; Ormiston JA; Spaulding C; Cohen SA; Fitzgerald PJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):146-54. PubMed ID: 21386089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
    Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
    Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial.
    Jensen LO; Maeng M; Thayssen P; Villadsen A; Krusell L; Botker HE; Pedersen KE; Aaroe J; Christiansen EH; Vesterlund T; Hansen KN; Ravkilde J; Tilsted HH; Lassen JF; Thuesen L
    EuroIntervention; 2011 Jul; 7(3):323-31. PubMed ID: 21729834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.